Blue Cross Blue Shield · Gimoti · US health-plan appeal rights

Gimoti denied as not FDA-approved for this use by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Gimoti denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Gastroparesis Gimoti / Domperidone EAP Coverage

The Blue Cross Blue Shield angle on Gimoti

## Why BCBS May Cite "Not FDA-Approved" for Gimoti

This denial reason, applied to Gimoti (metoclopramide nasal spray), is almost certainly an administrative error or a misclassification in BCBS's system. Gimoti received FDA approval for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. If your explanation of benefits states "not FDA-approved," the most productive first step is to contact BCBS member services immediately and ask them to verify the drug's FDA approval status before submitting a formal appeal.

## Why This Denial Is Appealable

A denial based on a factual inaccuracy — that an FDA-approved drug lacks approval — is among the strongest grounds for appeal and for external review reversal. The FDA approval letter and the current prescribing information are public documents that directly refute this basis. External reviewers, who are independent of the plan, are well positioned to correct denials grounded in factual error.

## Your Federal Appeal Rights

Informal correction first: Call member services and ask that the denial be reprocessed. Request a reference number for the call. If not corrected within a few business days, proceed to formal appeal.
Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal attaching the FDA approval documentation. Plans are required to have a complete internal appeal process with a written decision.
External review: If the internal appeal is denied (or if the plan does not correct the error), request independent external review under ACA §2719. Because the denial rests on a factual claim that can be objectively disproven, external review is likely to be resolved in your favor. Standard timeline is up to 45 days; expedited review is available if clinically urgent.

## Documentation to Gather

FDA approval confirmation: Print or download the FDA drug page for Gimoti (Evoke Pharma NDA) and the approved prescribing information — both are publicly available on FDA.gov.
Prescription and diagnosis records: Confirm that the drug was prescribed for the FDA-approved indication (diabetic gastroparesis in adults) so no off-label issue is conflated with the factual error.
Denial letter: Keep the original denial letter carefully — the stated reason "not FDA-approved" is evidence that the plan made a factual error.
Prescriber letter: A brief letter from your prescriber confirming the FDA-approved indication and the clinical rationale adds weight to the record.

## Criteria-Mapping Structure

Because the denial is factual rather than clinical, the mapping is straightforward:

| Plan's Stated Basis | Rebuttal Document | |---|---| | Drug is not FDA-approved | FDA approval record for Gimoti (NDA, approval date, indication) | | [Any secondary basis stated] | [Prescriber letter and chart documentation] |

Keep all submissions concise and documentary. The goal is to place the FDA's own record directly in front of the reviewer so no inference is required.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Gimoti

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.